Tenax Gets Patent OK for Oral Levosimendan (TNX-103) in Pulmonary Hypertension

 

• Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040
• There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030
• Once granted, this patent will significantly broaden Tenax’s U.S. intellectual property (IP) protection for a market with the potential to generate billions in future estimated annual sales
• Acting as both a potassium ATP channel activator and a calcium sensitizer, levosimendan is the only drug to show significant improvement in the 6-minute walk endpoint in this large patient population (Phase 2 HELP Study)
• Tenax intends to initiate a Phase 3 trial using this daily, oral formulation in 2023

https://www.biospace.com/article/releases/tenax-therapeutics-achieves-major-milestone-as-uspto-grants-notice-of-allowance-for-u-s-patent-application-covering-use-of-oral-levosimendan-tnx-103-in-pulmonary-hypertension-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef-/